Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02962648 · ClinicalTrials.gov registry record · Phase 3
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
A Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia, sponsored by Pharmacosmos A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
- 20
- Study locations
NCT02962648: Completed Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia, sponsored by Pharmacosmos A/S.
NCT02962648 is a Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia that has completed, run by Pharmacosmos A/S. The registered enrollment target is 103 participants, below the 189-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02962648, a Phase 3 study of Iron Deficiency Anemia and Iron Deficiency Anaemia, has completed, sponsored by Pharmacosmos A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
- 20
- Study locations
Study Summary
Evaluate safety and efficacy of intravenous (IV) iron isomaltoside/ferric derisomaltose re-dosing, in subjects who were previously treated with iron isomaltoside/ferric derisomaltose.
Primary Outcome
Safety Evaluate the number of subjects with adverse drug reactions (ADRs), defined as AEs that were assessed by the investigator as related or possible related to the investigational product.
Conditions Studied
Interventions
- DRUG Iron isomaltoside/ferric derisomaltose
Study Locations (20)
Florida
- Pharmacosmos Investigational Site - Doral
- Pharmacosmos Investigational Site - Hialeah
- Pharmacosmos Investigational Site - Miami
- Pharmacosmos Investigational Site - Miami
- Pharmacosmos Investigational Site - Miami
- Pharmacosmos Investigational Site - Miami Lakes
- Pharmacosmos Investigational Site - West Palm Beach
California
- Pharmacosmos Investigational Site - Chula Vista
- Pharmacosmos Investigational Site 1 - La Mesa
- Pharmacosmos Investigational Site 2 - La Mesa
- Pharmacosmos Investigational Site - Northridge
- Pharmacosmos Investigational Site - Porterville
Louisiana
- Pharmacosmos Investigational Site - Baton Rouge
- Pharmacosmos Investigational Site - Metairie
- Pharmacosmos Investigational Site - New Orleans
- Pharmacosmos Investigational Site - Shreveport
New Jersey
- Pharmacosmos Investigational Site - Plainsboro
New Mexico
- Pharmacosmos Investigational Site - Albuquerque
Tennessee
- Pharmacosmos Investigational Site - Chattanooga
Texas
- Pharmacosmos Investigational Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2017-01-09 |
| Est. Completion | 2018-06-12 |
| Phase | Phase 3 |
What the finished NCT02962648 record still lists
NCT02962648 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 189-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (46% lower).
The record links to 2 conditions, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 1 intervention - of which Iron isomaltoside/ferric derisomaltose is the first listed.
NCT02962648 names 20 study sites across 7 states, led by Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT02962648 about?
NCT02962648 is a clinical study titled "An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)". Evaluate safety and efficacy of intravenous (IV) iron isomaltoside/ferric derisomaltose re-dosing, in subjects who were previously treated with iron isomaltoside/ferric derisomaltose.
What is the current status of trial NCT02962648?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2017-01-09. Estimated completion is 2018-06-12.
What conditions does trial NCT02962648 study?
This clinical trial studies the following conditions: Iron Deficiency Anemia, Iron Deficiency Anaemia.
What interventions are being tested in trial NCT02962648?
The interventions under investigation include: Iron isomaltoside/ferric derisomaltose (DRUG).
Who is sponsoring clinical trial NCT02962648?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02962648 being conducted?
This trial has 20 study locations across California, Florida, Louisiana, New Jersey, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iron Deficiency Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02962648's enrollment target sits among peer trials
103 11th of 24 higher than 14 of 24 other Iron Deficiency Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Iron Deficiency Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
RECRUITING · Phase 3
-
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
RECRUITING · Phase 3
-
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
RECRUITING · Phase 3
-
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
COMPLETED · Phase 3
-
Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA
COMPLETED · Phase 3
-
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI